Skip to content
‹ Back to IndustriesSciences

Can Scientists Use ChatGPT for Scientific Research?

In December 2022, University of Colorado School of Medicine’s Casey Greene and Perelman School of Medicine’s Milton Pividori performed an experiment using ChatGPT to improve three research papers. The focus of the experiment was to see whether OpenAI’s language models were robust enough to supplement academic papers to make writing and revising manuscripts more efficient….

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By carey.scott · · Ai ToolsArtificial IntelligenceChatgptResearch Methods
Share

Key takeaways

01

In December 2022, University of Colorado School of Medicine’s Casey Greene and Perelman School of Medicine’s Milton Pividori performed an experiment using ChatGPT to improve three research papers.

02

The focus of the experiment was to see whether OpenAI’s language models were robust enough to supplement academic papers to make writing and revising manuscripts more efficient….

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

In December 2022, University of Colorado School of Medicine’s Casey Greene and Perelman School of Medicine’s Milton Pividori performed an experiment using ChatGPT to improve three research papers. The focus of the experiment was to see whether OpenAI’s language models were robust enough to supplement academic papers to make writing and revising manuscripts more efficient. Surprisingly for the academic community, the experiment proved successful, with their research finding that OpenAI’s models “can capture the concepts in the scholarly text and produce high-quality revisions that improve clarity.” More readable and accessible academic manuscripts sounds like a win for everyone involved, but how else can AI-supported chatbots support the academic community? Greene and Pividori’s research leaves many wondering whether scientists dealing in rigorous and highly-technical subjects can leverage ChatGPT for scientific research from start to finish.

ChatGPT was launched in November 2022 and got over 1 million users within the first week of its launch; OpenAI’s tool is clearly highly popular and gaining mainstream appeal, validating new use cases every week. The tool can perform complex tasks that save loads of time and energy, and can produce text like poetry, prose, computer code, and even topical research ideas. However, it’s not a perfect tool by any stretch. High level thought leaders in the tech community, including Steve Wozniak, warn that ChatGPT’s text generation can be riddled with errors. Obviously, anything of academic quality can’t have erroneous revisions applied.

Scientists use various types of research methods to gather information to develop their hypotheses and supplement academic texts, including digging for sources, conducting hypothetical scientific models to prove their research, running surveys for new data, and more. With ChatGPT Plus hot on our heels, should scientists start to use ChatGPT for scientific research? How confident can they be in its efficacy? Justin Bean, author of What Could Go Right and an experienced sustainability and smart city strategist working with Fortune 500s and cutting-edge start-ups, weighs in with his take. Bean is highly familiar with the research process; he spent many years as a clean tech and green energy consultant, where he conducted layered and rigorous research of financial data, venture capital investments, trend reports and more.

Justin’s Thoughts:

“So, if Siri gave everyone a digital assistant, ChatGPT gives everyone a digital intern. This means it can do way more work for us and including in science. So, a lot of the work in science and data analysis is all about gathering and blending and cleaning and compiling data, and about making interpretations that lead to some kind of insight, which they can then take and do science with.

Now because of ChatGPT, a lot of that early stage can be done by an AI and that’ll free up scientists to have a lot more time doing the science. But not just that, it’s going to free a lot of people up to be able to do science who aren’t conventional scientists and people who don’t have PhDs. This is because it’s going to do a lot of that initial work and be able to explain it in everyday layman’s terms for you and me to be able to do the science.

And I think that’s going to democratize a lot of inventions and a lot of science as innovators from around the world and different perspectives, it will bring their perspectives to science and leverage the information they can get through chatGPT. Now, as this develops, all these AIs are going to become more and more specialized.

So you may have a specialized artificial intelligence for cancer science and detection, and another one for weather science or climate science. Many different ones will proliferate. In addition, we’re going to have autonomous economic agents that will take that information and go out and acquire materials or goods or contracts for us just to make a lot of that process a lot easier and make us all more effective.”

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

C
carey.scott
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

C
carey.scott

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512